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Abstract 
Objectives:  Neurogenic inflammation plays a key part in the development and 
continuation of migraine headaches.  Treatment of migraines includes acute attack 
medications, avoidance of triggers, and preventative treatment.  Currently there are no 
FDA approved preventative medications for treatment of pediatric migraines.  Pediatric 
migraines have long been unrecognized and undertreated.  This systematic review 
evaluates RCT’s that have studied prophylactic treatment of migraines with topiramate. 
Methods:  An thorough search of PubMed, Medline, Cinhahl, and EBM Reviews of the 
Pacific University Library Database which compiles the Cochrane Database of 
Systematic Reviews, ACP Journal Club, and Cochrane Central Register of Controlled 
Trials for potential randomized, double-blind, placebo-controlled, parallel studies was 
conducted to discover studies connected to the question. 
Results:  A pooled analysis of three trials involving 307 patients suggest a moderate 
benefit when topiramate is given to children between 6 and 17 for prevention of 
migraine headaches.  The decrease in migraine frequency reported by was statistically 
significant in two of the studies. 
Conclusions:  Topiramate is an effective preventative medication, with mild to 
moderate side effects, for managing pediatric migraines. 
Keywords:  migraine, pediatric, treatment, prevention 
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Introduction 
 Migraine headaches, present in both the adult and pediatric population, can 
cause pain, a decrease in quality of life, missed work or school days and impaired 
performance in daily activities.  Migraines are familial disorders that are characterized 
by periodic headaches that are variable in manifestation, intensity, frequency, and 
period (International Headache Society, 2004).  Although migraines often occur on one 
side, may be accompanied by an aura, and are associated with nausea and vomiting, 
they can present in a variety of ways, as described in detail by the International 
Headache Society (IHS) 2004.  Migraine headaches often occur in stages.  Although 
every patient does not experience or describe each of the periods it does discount the 
migraine diagnosis.  The prodromal stage occurs prior to the aura or headache.  Stage 
two, the aura, does not manifest in all patients.  In the past, migraine headaches with an 
aura were called classic migraines, whereas, migraines without an aura were referred to 
as common migraines.  Stage three, the headache, also does not accompany every 
migraine.  The postdrome phase is often described by patients as a headache 
hangover.  Typically migraines are described as a syndrome aggravated by normal 
physical activity, nauseating, and are accompanied by some degree of photophobia 
and/or phonophobia.  In the pediatric population, the under diagnosed migraine is the 
most widespread type of reoccurring headache (Cruse, 2010).  Nearly 2.5% of all 
children under the age of seven have chronic migraine headaches (Cruse, 2010).  
Using census data from 2008, this means that of the 33.2 million U.S. children under 
age seven, 830,660 suffered migraines.  The trend continues to climb through 
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adolescence.  By the age of 17 nearly 8% of boys and 25% of girls suffer from recurrent 
migraines (Cruse, 2010).   
 Despite the prevalence of migraines in the pediatric population, much of the 
information regarding prophylactic treatment for children comes from adult based 
studies.  The beta-blocker propranolol is the prophylactic treatment most commonly 
used for children however, its use is primarily based upon evidence from adult studies 
(Cruse, 2010).  The aim of this systematic review is to investigate pediatric migraine 
prophylaxis treatment.  This study specifically compares the use of topirimate to placebo 
to decrease the frequency of migraine headaches in children. 
Review of the Literature 
Headaches, whether in children, adolescents or adults, are classified as primary 
or secondary in nature.  Secondary headaches are caused by a specific etiology, 
whereas a primary headache is inherent to the nervous system (Hershey, 2010).  The 
three types of primary headaches recognized by the IHS are cluster headaches, 
tension-type headaches, and migraines.  Cluster headaches, more common in men, are 
often unilateral and associated with symptoms of nasal congestion, rhinorrhea, facial 
sweating, or eyelid edema.  Tension-type headaches, due to muscle contraction, are 
not usually accompanied by nausea, vomiting, photophobia, or phonophobia.  The 
subclasses of migraine headaches recognized by the International Headache Society 
(IHS) are the migraine with aura, migraine without aura, childhood periodic syndromes, 
retinal migraine, complications of migraine and probable migraines (International 
Headache Society, 2004).     
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According to Kalra and Elliott (2007), an incomplete understanding of the 
pathophysiology of migraine headaches in general may have led to the setback in 
treating migraine headaches, specifically.  The pathophysiology of migraine headaches 
is shifting from a purely vascular theory to a neuronal hyper-excitability theory which 
combines elements from both (Robertson 2010).  According to the hyper-excitability 
theory, the trigeminovascular system is activated and an inflammatory cascade ensues.  
In the newer trigeminovascular theory, neuronal dysfunction leads to a series of 
intracranial and extracranial changes (Robertson 2010).  A significant change occurs, 
within the brainstem, which is visible on PET scans of migraine patients during an acute 
migraine attack (Cruse 2010). The locus ceruleus projections start a spreading 
depression, which is thought to be from where the patients’ aura stems (Cruse 2010).  
As the cortical spreading depression moves to the central sulcus and meningeal 
trigeminal fibers, the stimulation causes blood vessels to dilate and neuropeptides to be 
released (Robertson 2010).  Neuropeptides such as Substance P, 5-HT and others 
cause a sterile neurogenic inflammation resulting in a headache.    
 Pediatric migraine headache is a serious concern for parents.  Not only do 
parents lose work time to care for their children, but they are concerned with the 
increased frequency of school absences and their child’s inability to participate in social 
and family activities.  Migraine headaches can become a chronic disabling problem that 
extends through childhood and into adolescence and adulthood.  By considering a 
regime that includes prophylactic treatment, along with acute attack management, 
coupled with avoiding risk factors, it may be possible to prevent the continuing affliction 
and enhance the quality of life for these patients (Hershey 2010).   
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The healthcare cost of migraine treatment in the United States is enormous.  In 
2000 there were three million migraine headache related emergency department visits, 
at a predicted cost ranging from 600 million to 2 billion dollars (Goldberg, 2005).  The 
total cost of migraine care is estimated to be between 13 and 17 billion dollars divided 
between direct healthcare service costs and indirect costs, which factor in things such 
as lost productivity (Goldberg, 2005).  The World Health Organization (WHO) has listed 
migraine headaches as nineteenth in the diseases world-wide that cause disability.  
Taking socioeconomic concerns into consideration, the need for developing a plan for 
treating acute attacks in combination with considering the need for prophylactic 
medication is of foremost importance.   
The process of obtaining a headache history from younger children can be 
challenging.  It can be difficult to get a young child to understand the concepts of onset, 
triggers, and associated symptoms.  In addition, a child’s ability to adequately self report 
is limited by their ability to rely on memory of an event or sense of time.  It is important 
to avoid assuming that a younger child’s migraine is similar to that of adolescent or adult 
migraine, or that a lack of adult type symptoms means the headache is not a migraine.  
Children under the age of twelve generally have more morning attacks; the headache is 
shorter in duration and is often relieved by sleep (Hershey, Powers, Vockell, LeCates, 
and Kabbouche, 2002).  In fact, International Classification of Headache Disorders-2nd 
edition has reclassified pediatric migraines as greater than one hour in length, bilateral 
rather than just unilateral, and may be frontotemporal (IHS, 2004).  Once the migraine 
diagnosis has been confirmed, practitioners can establish the headache severity and 
frequency so that treatment options can be evaluated.   
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Children with greater than three migraine headache episodes in a month should 
be considered for prophylactic treatment (Hershey et al., 2002).  In addition, if the 
migraine attack is severely disabling, according to a pediatric scoring system such as 
the Pediatric Migraine Disability Assessment Scale (PedMIDAS) (Cincinnati Children’s 
Hospital Medical Center, 1999-2010), prophylactic treatment should be considered 
(Hershey, 2004).  The PedMIDAS tool addresses the number of full school days 
missed, partial days missed, a student’s ability to function at less than half of their ability 
at school, inability to perform home tasks, and reduced participation in outside activities 
reported over a period of three months (Cincinnati Children’s Hospital Medical Center, 
1999-2010).  The tool also takes into consideration the parents rating of the child’s 
headache frequency and severity.  Higher scores correspond to greater headache 
severity and an increased need for prophylactic treatment (Hershey, 2004).   
At present there are no FDA approved medications for the prophylactic treatment 
of pediatric migraines (Lewis et al., 2009).  Topiramate has been identified as a 
promising prophylactic pediatric migraine medication regime, as it has been used to 
treat pediatric partial onset seizures and primary generalized tonic-clonic seizures in 
children as young as two years old (Ferraro & DiTrapani, 2008). It is important to 
evaluate and consider the safety and tolerability using topiramate in the pediatric 
population.  Parents and providers must carefully weigh the benefit of the medication 
against the side effect profile.  Ferraro and DiTrapani, (2008) conducted a review of 
several studies using topiramate for pediatric migraines, and found the most common 
side effects among children were weight loss, anorexia, abdominal pain, tiredness, 
difficulty with concentration, and paresthesias.  They also found that the side effects 
11 
tended to decline over time.  Side effects are often worse during the titration period 
compared to the maintenance period (Meador, Loring, Hulihan, and Karim, 2003). 
Similar reports of side effect have been found in adult populations.   
Practitioners armed with studies that are of high quality measuring the change in 
headache frequency and severity, and considering issues of patient safety, will be able 
to assist parents in choosing a treatment plan.  A migraine headache treatment strategy 
may include utilizing acute attack medications, identifying and making lifestyle changes 
and a prophylactic medication regime.  In some cases all three components will be 
important for improving the patient’s quality of life.   
Methodology 
 This is a systematic review of randomized, double-blind and placebo controlled, 
parallel trials.  A comprehensive literature search of PubMed (1966-2010), Medline 
(1950-present), Cinhahl (1988-2010) and EBM Reviews of the Pacific University Library 
Database which compiles the Cochrane Database of Systematic Reviews (2005-Sept. 
2010), ACP Journal Club (1991-August 2010) and Cochrane Central Register of 
Controlled Trials 3rd quarter 2010.  The searches were conducted using the following 
terms: migraine and pediatric or children or adolescents, treatment and preventative.  
Studies in English that were completed since 2000 were selected for inclusion.  Three 
trials met the criteria of being randomized, double-blind, placebo-controlled and parallel 
studies.  An additional search conducted through Medline (1950-present) utilized the 
“related articles” tool to find additional articles.  The bibliography for each of the three 
studies selected was cross referenced to search for possible studies meeting the criteria 
for this systematic review.  A search of ClinicalTrials.gov was done to identify any recent 
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trials that may be available.  Only one similar study was identified but, omitted as it was 
limited to basilar migraines.  
The decision to limit studies to randomized, double-blind and placebo-controlled 
studies stems from work done by Yoon, Savidou, Diener and Limmroth ( 2005) who set 
a standard of study design.  It was their idea to utilize a high quality study design that 
would compare a single drug against a placebo rather than confounding the research by 
comparing different drugs.  The randomized studies that utilize a placebo lay the 
groundwork for future studies that compare efficacy and safety between classes (Yoon 
et al. 2005).  
Results 
Study Characteristics 
The search strategy for this systematic review yielded three randomized, double-
blind, placebo-controlled, parallel trials.  Evaluation of the studies indicated that the 
format for the trials were similar in design (see Table 1).  All three randomized trials 
incorporated a period for screening potential subjects followed by a four week period for 
collecting baseline headache data.  During this period, prior to randomization or 
dispensing any medication, subjects kept headache data (Lakshmi et al. 2007; Lewis et 
al. 2009; Winner et al. 2005).  The next phase, a double-blind period, involved titration 
of either topiramate or placebo followed by a maintenance phase which ranged in length 
from 12 to 16 weeks.  All subjects were analyzed in the group they were randomly 
assigned to.   
There was clinical homogeneity with respect to use of acute migraine attack 
medications allowed.  Lewis et al. allowed nonprescription analgesics, NSAID’s, 
13 
triptans, ergot derivatives and DHE, so long as they were not used more than 14 
treatment days in a month.  Winner et al. (2005) allowed acute abortive treatment that 
did not exceed more than 12 days a month with analgesics or more than 8 days a 
month of triptans or ergotamines.  Lakshmi et al. (2007) allowed use of acute 
medications but did not specify any limitation on use.  Two trials reported no statistical 
significance in the number of rescue medications used (Lakshmi et al. 2007; Lewis et al. 
2009).  One study utilized a 24 hour rule to define the migraine period, another a 48 
hour rule for the primary outcome and a 24 hour rule for the secondary outcomes, and 
the third did not specify.  The 48 hour rule simply states that a single headache episode 
encompasses 48 hours.  If a headache occurs less than 48 hours after a previous 
headache, it is considered a worsening of the previous headache (Lewis et al. 2009).  
Similarly, the 24 hour rule considers two headaches within 24 hours of each other the 
same headache.  All three studies utilized the IHS migraine definition for inclusion in the 
trials. 
Data Synthesis 
Pooled data included results from 307 subjects from three randomized, double-
blind, placebo-controlled, parallel trials.  The combined results were used to evaluate 
the primary outcome which is a reduction in monthly migraine attack rate compared to 
the baseline period.  The migraine attack rate was expressed as the number of 
migraines per month (Lakshmi et al. 2007; Lewis et al. 2009; Winner et al. 2005).  
Several secondary outcomes measured by one or more of the studies include the 
number of break through acute attack medications, functional disability, school 
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absenteeism, and a responder rate which reports a ≥50% reduction in the monthly 
migraine attack rate. 
Primary Outcome 
 The combined results from all three trials suggest a benefit when using 
topiramate as a standard preventative therapy to reduce the monthly migraine 
frequency in children and adolescents age 6 to 17 (Lakshmi et al. 2007; Lewis et al. 
2009; Winner et al. 2005) .  The decrease in frequency did not show statistical 
significance (P=.061) in one of the studies but was statistically significant in the other 
two studies (P=.025) and (P=.016) (see Table 2).  The dose of topiramate given to the 
subjects varied in one arm of one study.  Lewis et al. (2009) compared both a 50mg 
dose of topiramate and a 100mg dose of topiramate to placebo.  The 50mg dose 
received by 33 subjects was one half of the dose received by the remaining 170 
topiramate subjects.  The subjects in Lakshmi et al. (2007) received 100mg and the 
subjects in Winner et al. (2005) received 2-3mg/kg/day which when based on the mean 
subject weight of 49.2kg is 98.4mg to 147.6mg of topiramate.  Lewis et al. (2009) 
calculated the 100mg arm separate from the 50mg arm as a secondary analysis, and 
found the 100mg dose, when compared to placebo, consistently demonstrates a 
decrease in the monthly migraine rate (P=.016).  The 50mg dose of topiramate yielded 
a decrease in monthly migraine rate that was not statistically significant (P=0.798).   
Secondary Outcomes 
Two trials tracked the number of break through acute attack medications used.  
Neither Lakshmi et al. (2007) or Lewis et al. (2009) reported statistical significance in 
the difference in quantity of acute medications used from the baseline period to the end 
of the trial in either the topiramate or placebo arm.  Lakshmi et al. (2007) assessed 
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functional disability using the PedMIDAS tool.  The decreased score was statistically 
significant in the topiramate arm which dropped from baseline 50.66(±32.1) to 
10.42(±6.39) at the end of the study.  The placebo group dropped from 42.66(±27.5) to 
23.7(±19.1) (P=0.003).  The decline in school absenteeism was significant.  In Lakshmi 
et al. (2007) the number of school days missed declined from 4.04 days/month at 
baseline to 1.47 days/month for the topiramate arm compared to an increase in days 
missed in the placebo arm (P=.002).  The studies evaluated the percentage of subjects 
that had reduction in headache frequency.  When a subject responds to the treatment 
by having a decrease in headache frequency the subject is part of the responder rate.  
A responder is a subject that has a reduction in headache frequency.  The percentage 
of subjects in the >50% responder rate achieved statistical significance in the Lakshimi 
et al. (2007) trial and in the 100mg arm of the Lewis et al. (2009) trial.  The responder 
rate for Winner et al. (2005) is 54.6% for the topiramate group and 46.9% in the placebo 
group.   
Side Effects/Adverse Affects 
 Overall, all three trials reported that subjects tolerated topiramate well (Lakshmi 
et al. 2007; Lewis et al. 2009; Winner et al. 2005).  Most adverse events were 
considered by the authors to be mild to moderate in nature.  The most frequently 
reported adverse affects in the topiramate group were weight loss (27%), upper 
respiratory infection (17%), anorexia (13%), and paresthesia (13%)  (see Table 4).  The 
two side effects with the greatest difference between the placebo group and the 
topiramate group were weight loss and paresthesia.  With respect to weight loss, the 
mean change from baseline body weight to end of study weight ranged between ˗0.7± 
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3.9kg to -0.3±3.2kg in the topiramate group compared a range of 1.4±2.6kg to 
0.8±2.3kg among the placebo subjects (Lakshmi et al. 2007; Lewis et al. 2009; Winner 
et al. 2005).  None of the studies reported a clinically significant change in lab values 
from the baseline period to the end of the study.   
 With respect to serious adverse events, there were eight reported between two 
studies.  One of the studies, Lakshmi et al. (2007) had no reported adverse events.  
Two adverse events were in subjects not yet randomized to a treatment group.  Of the 
serious adverse events among randomized individuals, one subject had back pain, one 
had an unrelated injury, one had a severe migraine, one subject had suicidal ideation 
and two subjects had infections. 
Study Limitations 
 Each of the studies was randomized, double-blind, placebo-controlled and 
parallel.  The quality of the studies was not limited by design or execution.  There was 
heterogeneity with respect to the intervention.  Lakshmi et al. (2007) used a standard 
100mg dose where as Winner et al. (2005) titrated a dose up to 2-3mg.kg/day.  Lewis et 
al. (2009) compared a 50mg/day arm and a 100mg/day arm to placebo.  The studies 
were relevant to the study question at hand.  The studies addressed the patient 
population, compared topiramate to placebo and addressed similar outcomes.  All three 
studies identified and addressed the reasons withdrew from the RCT.  Each RCT clearly 
stated the number of patients lost to follow up.  Loss to follow up was 3% in Lewis et al. 
(2009) and 4% in  Lakshimi et al. (2007) and Winner et al. (2005). Taken individually the 
studies had small numbers of patients however; together there were enough patients to 
provide power in this systematic review.   
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Discussion, Conclusion, Implications & Recommendations 
Discussion 
The studies included in this systematic review reveal a reduction in monthly 
migraine frequency among 100mg/day topiramate users compared to the placebo group 
or the arm of one trial that received only 50mg/day of study medication.  The headache 
frequency in Lakshmi et al. (2007) fell from 16.14±9.35 headache days per month to 
4.27±1.95 headache days versus placebo of 13.38±7.78 to 7.48±5.94.  Lewis et al. 
(2009) demonstrated a frequency reduction of 72.2% versus 44.4% in the placebo 
group.  Winner et al. (2005) had a reduction in migraine frequency that approached 
statistical significance in the ITT (intention to treat) population.  When Winner et al. 
(2005) calculated the migraine frequency using the per protocol population, the 
reduction in monthly migraines was statistically significant.  The number of headache 
days fell by 2.8±2.4 days in the topiramate group compared to 2.2±2.1days in placebo. 
 There was clinical homogeneity with respect to use of acute migraine attack 
medications allowed.  Lewis et al. allowed nonprescription analgesics, NSAID’s, 
triptans, ergot derivatives and DHE, so long as they were not used more than 14 
treatment days in a month.  Winner et al. (2005) permitted acute abortive treatment that 
did not surpass 12 days a month with analgesics or more than 8 days a month of 
triptans or ergotamines.  Lakshmi et al. (2007) allowed use of acute medications but did 
not spell out limitation on use.  Two trials reported no statistical significance in the 
number of rescue medications used (Lakshmi et al. 2007; Lewis et al. 2009).   
An area of heterogeneity identified as a possible confounder is the definition of a 
migraine period.  One study clearly stated that they utilized a 24 hour rule, another a 
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stated they used a 48 hour rule for the primary outcome but a 24 hour rule for 
secondary outcomes, and the third did not specify.  The 48 hour rule simply states that 
a single headache episode encompasses 48 hours.  If a headache occurs less than 48 
hours after a previous headache, it is considered a worsening of the previous headache 
(Lewis et al. 2009).  Similarly, the 24 hour rule considers two headaches within 24 hours 
of each other the same headache.  The size of the decrease in the monthly migraine 
rate had variability due to the number of migraine periods available in each of the 
studies.  As stated earlier, Lakshmi et al. (2007) utilized a 24 hour migraine rule which 
provided 84 migraine periods over the course of the study.  Lewis et al. (2009) used a 
48 hour rule which meant the subjects had only 42 migraine periods to evaluate.  
Winner et al. (2005) did not specify the hour rule used, but his data aligns with Lewis’ 
subjects with 56 migraine periods to evaluate. 
All three trials looked at the decrease in monthly migraine frequency as a primary 
outcome.  All three also evaluated various responder rates.  Responder rates provide 
the percent of patients that have a given level of response to a treatment.  All three trials 
provided a ≥50% responder rate which indicates the percentage of subjects that had at 
least a 50% reduction in migraine frequency.  The topiramate subjects in Lakshmi et al. 
(2007) show a 95.2% responder rate compared to 52.4% among the placebo group.  In 
Lewis et al. (2009), the responder rate was significant among the 100mg/day arm, but 
not among the 50mg/day group.  The percentage of responders was 45% for placebo, 
46% for the 50mg arm and 83% for the 100mg arm.  Winner et al. (2005) reported a 
54.6% response among topiramate users and 46.9% for the placebo group.   
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Secondary efficacy measures included quality of life, absenteeism, migraine 
severity and the number of rescue medications used.  Among topiramate users quality 
of life scores decreased reaching statistical significance and decreased absenteeism 
approached statistical significance (Lakshmi et al. 2007).  The decreased PedMIDAS 
score, coupled with fewer school days missed, points to an overall improvement in a 
childs’ quality of life.  PedMIDAS scores or absenteeism data were not collected or 
reported by Lewis et al. (2009) or Winner et al. (2005).  The use of rescue medications 
has been the mainstay of pediatric migraine headache management.  The use of rescue 
medications carries the risk of developing MOH (medication overuse headaches).  
Neither one of the studies that tracked the number of rescue medications used showed 
a statistically significant decrease in medication use when comparing topiramate to 
placebo. 
The side effect profile of every medication is of key importance, as it corresponds 
directly to patient compliance.  It is well known that patients will stop a medication 
because of the side effects.  Each of the three RCT’s kept a record of side effects and 
frequency.  The most common adverse effect among topiramate users was weight loss 
followed by URI, anorexia, and paresthesias.  None of the subjects died from the trial 
nor did any experience any serious side effects.  It is significant that topiramate has 
been used to treat pediatric seizures at much higher doses (200mg/day for 
monotherapy in >10 y/o or 5-9mg/kg/day as adjunct in 2-16y/o) than was utilized for 
migraine prevention in the RCT’s (Hershey et al. (2002). 
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Conclusion 
This systematic review investigates pediatric migraine prophylaxis treatment.  
This study specifically compares the use of topirimate to placebo to decrease the 
frequency of headaches in children.  The results of all three studies show a reduction in 
the monthly migraine frequency compared to placebo at the 100mg/day dose or at 2-
3mg/kg/day.  The 50mg/day dose evaluated in one arm of one trial did not show a 
statistically significant decrease in monthly migraine frequency for topiramate compared 
to placebo.  The decrease in Winner et al. (2005) unlike the other two studies did not 
demonstrate statistical significance.  Winner et al. (2005), attributes the lack of statistical 
significance to calculating outcomes from the total titration and maintenance period, as 
opposed to using the maintenance period alone.  Medication often does not reach its 
efficacy while the dose is being titrated.  The other two studies evaluated the 
maintenance period separately from the titration period. 
Implications 
Migraine headaches in children have long gone unrecognized and therefore have 
been undertreated (Hershey, 2010).  Armed with the 2004 IHS report, which serves to 
clarify the pediatric migraine diagnosis, providers have a system in place to identify 
migraine headaches.  A migraine headache treatment strategy may include acute attack 
medications, identifying migraine headache triggers, and making lifestyle changes to 
address the triggers, and finally utilization of prophylactic medications (Ferraro & 
DiTrapani, 2008).  In some cases all three components will be important for improving 
the patient’s quality of life.  Topiramate is associated with a decrease in monthly 
migraine frequency and increased quality of life score measured by the PedMIDAS tool.  
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Coupled with a side effect profile considered mild to moderate in nature by all three 
trials, practitioners have another option to include as a pharmaceutical option treating 
pediatric migraines.   
Recommendations 
 This systematic review of three moderate quality, (see Table 3) randomized, 
double blind, placebo controlled, parallel studies consistently demonstrated benefit that 
outweighed the risks for utilizing topiramate for migraine prophylaxis in pediatric 
migraine patients.  Taken together, the data collected from the three randomized trials 
indicate topirimate is recommended for pediatric migraine prevention among patients 
meeting the IHS criteria for a migraine headache (see Table 3).  More research is 
needed to compare the value of topiramate to other prophylactic migraine headache 
medications.  This systematic review compared topiramate to placebo but did not 
consider the other options available.  Further research may have an impact on the 
outcome of this study.   
One potential major confounder identified was the difference between a 
50mg/day dose and a 100mg/day dose.  The study utilizing the 50mg dose ran joint and 
separate calculations and clearly stated the results of both.  The other confounder was 
the definition of the migraine period which varied from 24 to 48 hours.  Both of these 
confounders tended to underestimate the treatment effect.  As such, future studies, at 
the higher dose with similar migraine period definitions will likely yield an even stronger 
recommendation for topiramate in children’s preventative migraine treatment. 
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Appendixes 
Table A 
Characteristic of Included Randomized Clinical Trials 
Author, Year 
No. of 
Facilities 
Location No. of Patients 
Migraine 
Definition 
Demographics 
Winner et al., 
2005 
17 medical 
centers 
United States 162 IHS1 Mean age 
11.1±2.5 
%Female 48% 
Race 
Caucasian121 
Black 33 
Other 3 
Lakshmi et al., 
2007 
1 center India 42 IHS1 Mean age 
10.5±1.4 
%Female 31% 
Race 
Other 42 
Lewis et al., 
2009 
31 US and non-
US sites 
World-wide 103 IHS1 Mean age 
14.2±1.6 
%Female 61% 
Race 
Caucasian 88 
Black 11 
Other 4 
1
 IHS migraine criteria for pediatrics states that pediatric migraines are greater than one 
hour  in duration, may be bilateral, may be frontal-temporal and photophobia and/or 
phonophobia can be inferred from behavior.   
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Table B 
Comparison of Primary Efficacy Analyses 
 placebo 
50mg 
topirimate 
100mg 
topiramate 
placebo topiramate placebo topiramate 
Study Lewis et al (2009) Lakshmi et al (2007) Winner et al (2005) 
Mean Baseline 
no./mo 
4.1 4.1 4.3 13.38 16.14 5.5 5.4 
Double-blind 
No/mo 
2.4 2.4 1.3 7.48 4.27 3.1 2.3 
Reduction in 
No.Migraines/o 
1.7 1.7 3.0 5.9 11.87 2.4 3.1 
Statistical 
Significance 
(p- value) 
 0.798 0.016  0.025  .061 
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Table C 
Grade Table 
Topiramate compared to Placebo for Pediatric Migraine Headache 
Patient or population: Patients with Pediatric Migraine Headache 
Settings: outpatient 
Intervention: topiramate 
Comparison: placebo 
Outcomes Illustrative comparative 
risks* (95% CI) 
Relativ
e 
effect 
(95% 
CI) 
No of 
Participant
s 
(studies) 
Quality of the 
evidence 
(GRADE) 
Comments 
Assumed 
risk 
Correspondi
ng risk 
 
Placebo Topiramate 
    
Reduction in 
Monthly 
Migraine 
Frequency 
(Baseline-last 
12 
weeks/baseli
ne x1 00. 
Scale from: 0 
to 28. 
Follow-up: 
mean 25 
weeks1 
The mean 
reduction 
in monthly 
migraine 
frequency 
in the 
control 
groups was 
3.2 
days/mont
h 
The mean 
Reduction in 
Monthly 
Migraine 
Frequency in 
the 
intervention 
groups was 
4.79 higher 
(0 to 0 
higher) 
 
307 
(3 studies) 
⊕⊕⊕⊝ 
moderate2,3,4,5,6 
Lewis et al 
used a 48 
hour 
migraine 
rule.  
Lackshmi et 
al used a 
24 hour 
migraine 
rule.  
Winner et al 
did not 
specify. 
Categorical 
Response 
Rate: 
Subjects 
with >50% 
reduction in 
monthly 
migraine 
days 
percent.  
Scale from: 0 
to 100. 
Follow-up: 
mean 25 
weeks 
The mean 
categorical 
response 
rate: 
subjects 
with >50% 
reduction 
in monthly 
migraine 
days in the 
control 
groups was 
48.1 
percent 
The mean 
categorical 
response 
rate: subjects 
with >50% 
reduction in 
monthly 
migraine 
days in the 
intervention 
groups was 
69.7 higher 
(0 to 0 
higher) 
 
307 
(3 studies) 
⊕⊕⊕⊝ 
moderate7,8,9,10,
11
 
Greater 
than 50% 
reduction in 
rate is the 
commonly 
accepted 
tool 
however 
Winner et al 
and Lewis 
et al also 
discussed a 
> 
75%respod
er rate.   
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Decrease in 
functional 
disability 
measured by 
the 
PedMIDAS  
PedMIDAS 
Score.  Scale 
from: 0 to 51. 
Follow-up: 16 
weeks 
The mean 
decrease 
in 
functional 
disability 
measured 
by the 
PedMIDAS 
in the 
control 
groups was 
18.96 days 
with 
functional 
limitation 
The mean 
Decrease in 
functional 
disability 
measured by 
the 
PedMIDAS 
in the 
intervention 
groups was 
40.24 higher 
(0 to 0 
higher) 
 
42 
(1 study) 
⊕⊕⊕⊕ 
high12,13,14 
Quality of 
life was 
assessed 
by the 
PedMIDAS 
score.  The 
score 
measures 
disability 
based on 
school 
function, 
school 
attendance, 
and 
functioning 
at home. 
Decreased 
school 
absenteeism 
days per 
month.  Scale 
from: 0 to 28. 
Follow-up: 16 
weeks 
The mean 
decreased 
school 
absenteeis
m in the 
control 
groups was 
1 day per 
month15 
The mean 
Decreased 
school 
absenteeism 
in the 
intervention 
groups was 
2.6 higher 
(0 to 0 
higher) 
 
42 
(1 study) 
⊕⊕⊕⊕ 
high 
Reported 
by 
Lackshmi et 
al. 
Decrease in 
body weight 
tenths of a 
kilogram lost 
Follow-up: 
mean 25 
weeks 
The mean 
decrease 
in body 
weight in 
the control 
groups was 
9 tenths of 
a kilogram 
gained 
The mean 
Decrease in 
body weight 
in the 
intervention 
groups was 
35 tenths 
lost 
(0 to 0 
higher) 
 
307 
(3 studies) 
⊕⊕⊕⊝ 
moderate16 
There were 
several 
safety 
issues 
listed in the 
study.  URI, 
paresthesia
, abdominal 
pain, 
anorexia 
and weight 
loss were 
listed most 
often as a 
side effect. 
*The basis for the assumed risk (e.g. the median control group risk across studies) is 
provided in footnotes.  The corresponding risk (and its 95% confidence interval) is 
based on the assumed risk in the comparison group and the relative effect of the 
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intervention (and its 95% CI). 
 
CI: Confidence interval;  
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate 
of effect.   
Moderate quality: Further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
1
 The pretreatment phase ranged from 4 to 16 weeks and included screening, washout 
and titration.  In each of the studies there was a double-blind or maintenance phase 
ranging from 12 to 16 weeks.  One of the trials had a 6 week taper and exit phase. 
2
 In Lewis et al. patients were randomly assigned using permuted blocks and a 
computer-generated schedule with stratification to age (12-14years and 15 to 17 years).  
Patients all received identical appearing capsules.  This was a parallel-group study.  
Only one patient was lost to follow-up (from the topiramate 50mg/day group).  The study 
did not stop early.  In Lakshmi et al. patients were assigned using a random number 
table that was kept in sealed envelopes until the study was over.  Winner et al utilized an 
investigator that was supplied with a unique medication code for each subject.  The 
numbers were entered in order which then assigned each subject to one of two groups. 
3
 In Lewis et al the subjects were between 12 and 17 years of age and were assigned to 
receive either 50mg of topiramate, 100mg of topiramate or Placebo in a 1:1:1 ratio.  In 
Winner et al subjects received 2-3mg/kg/day.  In Lakshmi et al subjects received 
100mg/day. 
4
 There were 307 subjects.  In Winner et al there was no significant between differences 
observed for subjects discontinuing the study for any reason, as assessed by Fisher's 
exact test.  In Lewis et al 6 subjects did not finish the trial for medical reasons one in the 
placebo group, three in the 50mg group and two in the 100mg group.  Lakshmi et al had 
two subjects, one from each arm, lost to follow up secondary to economic reasons. 
5
 Winner et al was funded by Ortho-McNeil Pharmaceutical.  Lewis et al was funded by 
NIH grants, and Ortho-McNeil Janssen Scientific Affairs LLC. 
6
 In Lewis et al. the 100mg/day of topiramate statistically reduced the monthly migraine 
and headache day rates compared to the 50mg/day dose.  This may have 
underestimated the treatment effect.  (Lewis 933). 
7
 All studies had allocation well described, explained blinding, followed the ITT, did not 
stop early and reported several outcomes regardless of results. 
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8
 Doses of topiramate varied between studies.  Lakkshmi et al used 100mg, Winner et al 
used 2-3mg/kg/day, and Lewis et al used a 50mg arm and a 100mg arm. 
9
 No explanation was provided 
10
 The studies used different times for measuring a recurring headache versus a new 
headache.  Lakshmi et al used a 24 hour migraine rule.  If a migraine occurs less than 
24 hours after a prior headache, it is considered a worsening of the previous headache.  
Lewis et al used a 48 hour rule.  This difference gives Lakshmi twice as many migraine 
periods to evaluate. 
11
 Dose response gradient may affect outcomes. 
12
 The patients were randomized in the Lewis et al study to receive 100mg topiramate, 
50mg topiramate or placebo. 
13
 There was a dose response gradient identified in the Lewis et al study. 
14
 Presence of a dose response gradient may underestimate the treatment effect. 
15
 The control group increased absenteeism by one half day per month. 
16
 Patients in Lakshmi et al had a mean weight of 30kg whereas those in Lewis et al 
were 57.0kg and Winner et al was 49.2 kg. 
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Table D 
Adverse Events During the Double-Blind Phase   
 Lewis et al Lakshmi et al Winner et al Total 
 Topiramate Placebo Topiramate Placebo Topiramate Placebo Topiramate Placebo 
 URI 15 3 0 0 20 7 35 (17%) 10 (10%) 
Paresthesia 12 1 5 0 9 0 26 (13%) 1 (1%) 
Abdominal Pain 8 3 3 0 11 6 22 (11%) 9 (9%) 
Anorexia 7 1 5 3 14 4 26 (13%) 8 (8%) 
Injury 7 2 0 0 8 6 15 (7%) 8 (8%) 
Rhinitis 5 1       
Cough 4 0       
Viral Infection 4 1 0 0 10 2 14 (7%) 3 (3%) 
Pharyngitis 4 3 0 0 11 10 15(7.3%) 13(12.5%) 
Fatigue 5 2 4 2 6 6 15(7.3%) 10(10%) 
Nausea 5 2 0 0 5 3 10 (5%) 5 (5%) 
Dizziness 5 0       
Taste Perversion  4 0       
Insomnia 4 1       
Back Pain 2 3       
Conjunctivitis 4 1       
Sinusitis 3 1 0 0 11 6 14 (7%) 7 (7%) 
Asthma 2 0       
Pneumonia 2 0       
Fever 4 0 0 0 5 2 9 (4%) 2 (2%) 
Allergy 2 0       
Vomiting 2 1 0 0 8 3 10 (5%) 4 (4%) 
Nervousness 3 0       
Somnolence 2 0 4 0 9 3 15(7.3%) 3 (3%) 
Abnormal Vision 3 1       
Eye pain 2 2       
Weight loss 27 7 17 3 11 2 55(27%) 12(11%) 
The data is recorded by study in raw numbers.  The total includes the raw total and the 
percent of the total number of subjects in the study.  Subtracting the percent of adverse 
events in the placebo group from the adverse events in the topiramate group the 
highest incidence in the topiramate group is suggested.  Fields with numbers indicate 
responses.  Blank fields indicate that no data was collected.     
 
 
